Kenn Freddy Pedersen1, Jan Petter Larsen2, Ole-Bjørn Tysnes2, Guido Alves2. 1. From the Norwegian Centre for Movement Disorders (K.F.P., G.A.); Department of Neurology (K.F.P., G.A.) and Memory Clinic (K.F.P., G.A.), Stavanger University Hospital; Network for Medical Sciences (J.P.L.), University of Stavanger; and Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen, Norway. pekf@sus.no. 2. From the Norwegian Centre for Movement Disorders (K.F.P., G.A.); Department of Neurology (K.F.P., G.A.) and Memory Clinic (K.F.P., G.A.), Stavanger University Hospital; Network for Medical Sciences (J.P.L.), University of Stavanger; and Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen, Norway.
Abstract
OBJECTIVE: To examine the incidence, progression, and reversion of mild cognitive impairment in patients with Parkinson disease (PD-MCI) over 5 years. METHODS: A population-based cohort of patients with incident PD underwent repeated neuropsychological testing of attention, executive function, memory, and visuospatial abilities at baseline (n = 178), 1 year (n = 175), 3 years (n = 163), and 5 years (n = 150). Patients were classified as PD-MCI and diagnosed with dementia according to published criteria. RESULTS: Thirty-six patients (20.2%) fulfilled criteria for PD-MCI at baseline. Among those with normal cognition at baseline (n = 142), the cumulative incidence of PD-MCI was 9.9% after 1 year, 23.2% after 3 years, and 28.9% after 5 years of follow-up. Overall, 39.1% of patients with baseline or incident PD-MCI progressed to dementia during the 5-year study period. The conversion rate to dementia was 59.1% in patients with persistent PD-MCI at 1 year vs 7.2% in those with normal cognition during the first year (adjusted odds ratio 16.6, 95% confidence interval 5.1-54.7, p < 0.001). A total of 27.8% of patients with baseline PD-MCI and 24.2% of those with incident PD-MCI had reverted to normal cognition at study end, but the reversion rate decreased to 9.4% in those with persistent PD-MCI at 2 consecutive visits. Compared with cognitively normal patients, PD-MCI reverters within the first 3 years of follow-up were at increased risk of subsequently developing dementia (adjusted odds ratio 10.7, 95% confidence interval 1.5-78.5, p = 0.019). CONCLUSIONS: Early PD-MCI, regardless of persistence or reversion to normal cognition, has prognostic value for predicting dementia in patients with PD.
OBJECTIVE: To examine the incidence, progression, and reversion of mild cognitive impairment in patients with Parkinson disease (PD-MCI) over 5 years. METHODS: A population-based cohort of patients with incident PD underwent repeated neuropsychological testing of attention, executive function, memory, and visuospatial abilities at baseline (n = 178), 1 year (n = 175), 3 years (n = 163), and 5 years (n = 150). Patients were classified as PD-MCI and diagnosed with dementia according to published criteria. RESULTS: Thirty-six patients (20.2%) fulfilled criteria for PD-MCI at baseline. Among those with normal cognition at baseline (n = 142), the cumulative incidence of PD-MCI was 9.9% after 1 year, 23.2% after 3 years, and 28.9% after 5 years of follow-up. Overall, 39.1% of patients with baseline or incident PD-MCI progressed to dementia during the 5-year study period. The conversion rate to dementia was 59.1% in patients with persistent PD-MCI at 1 year vs 7.2% in those with normal cognition during the first year (adjusted odds ratio 16.6, 95% confidence interval 5.1-54.7, p < 0.001). A total of 27.8% of patients with baseline PD-MCI and 24.2% of those with incident PD-MCI had reverted to normal cognition at study end, but the reversion rate decreased to 9.4% in those with persistent PD-MCI at 2 consecutive visits. Compared with cognitively normal patients, PD-MCI reverters within the first 3 years of follow-up were at increased risk of subsequently developing dementia (adjusted odds ratio 10.7, 95% confidence interval 1.5-78.5, p = 0.019). CONCLUSIONS: Early PD-MCI, regardless of persistence or reversion to normal cognition, has prognostic value for predicting dementia in patients with PD.
Authors: Keith H Radler; Maria Anna Zdrodowska; Hollie Dowd; Tess E K Cersonsky; Edward D Huey; Stephanie Cosentino; Elan D Louis Journal: Parkinsonism Relat Disord Date: 2020-04-15 Impact factor: 4.891
Authors: Jeroen Hoogland; Lennard L van Wanrooij; Judith A Boel; Jennifer G Goldman; Glenn T Stebbins; John C Dalrymple-Alford; Connie Marras; Charles H Adler; Carme Junque; Kenn F Pedersen; Brit Mollenhauer; Cyrus P Zabetian; Paul J Eslinger; Simon J G Lewis; Ruey-Meei Wu; Martin Klein; Maria C Rodriguez-Oroz; Davide M Cammisuli; Paolo Barone; Roberta Biundo; Rob M A de Bie; Ben A Schmand; Alexander I Tröster; David J Burn; Irene Litvan; J Vincent Filoteo; Gert J Geurtsen; Daniel Weintraub Journal: Mov Disord Date: 2018-09-14 Impact factor: 10.338
Authors: Seok Jong Chung; Han Soo Yoo; Yang Hyun Lee; Hye Sun Lee; Byoung Seok Ye; Young H Sohn; Hunki Kwon; Phil Hyu Lee Journal: Hum Brain Mapp Date: 2019-05-14 Impact factor: 5.038